Risk factor
Very high price volatility
Profitability factor
Undervalued vs peers
About
AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the...
Company Valuation
Based on key historical and expected multiples, the stock is undervalued relative to its peers.
Target Price
The average target price of RCEL is 7.9 and suggests 91% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell